Vogiatzi Maria G, Autio Karen A, Mait Jeffrey E, Schneider Robert, Lesser Martin, Giardina Patricia J
Department of Pediatrics, New York-Presbyterian Hospital / Weill Medical College of Cornell University, New York, New York 10021, USA.
Ann N Y Acad Sci. 2005;1054:462-6. doi: 10.1196/annals.1345.063.
The pervasiveness of low bone mass (LBM) in beta-thalassemia (Thal) patients (pts) is escalating as the average life expectancy of these pts increases. Adolescence is a period of substantial bone accrual, which is crucial for future bone strength. Studies of LBM are prevalent among adults with Thal. However, limited information exists about bone accrual and LBM in adolescents with the disease. Thirty-one pts with beta-Thal (26 Thal major [TM], 5 Thal intermedia [TI]), aged 9-20 years (mean: 15.3 years), 14 males and 17 females, underwent measurement of spinal bone mineral density (BMD) by DEXA (Lunar, Prodigy). Height, weight, body mass index, and Tanner stage were assessed at the time of the BMD measurement. A total of 16.1% of the patients had normal bone mass (Z > or = -1), 22.6% had reduced bone mass (Z = -1 to -2), and 61.3% had low bone mass (Z < or = -2). BMD Z correlated with height and weight Z scores. Some 53.9% of subjects had normal gonadal function and 46.1% had induced puberty with gonadal steroids. BMD Z significantly worsened with age (P < .0001). However, there was no difference in the LBM prevalence between subjects with normal versus those with induced puberty: BMD Z was -2 or less in 71.4% of subjects with normal puberty versus 66.7% in those with induced puberty. Our results indicate a high prevalence of LBM among adolescents with Thal regardless of adequate transfusion and chelation regimens. Bone accrual was found to be suboptimal in adolescents with normal or induced puberty. Thus, calcium and vitamin D supplementation with antiresorptive therapies should be evaluated in the adolescent Thal pt with close monitoring of growth and sexual development.
随着β地中海贫血(Thal)患者平均预期寿命的增加,这些患者中低骨量(LBM)的普遍性正在上升。青春期是骨量大量增加的时期,这对未来的骨骼强度至关重要。关于LBM的研究在成年Thal患者中很普遍。然而,关于该疾病青少年的骨量增加和LBM的信息有限。31例9至20岁(平均15.3岁)的β地中海贫血患者(26例重型地中海贫血[TM],5例中间型地中海贫血[TI]),14例男性和17例女性,通过双能X线吸收法(DEXA,Lunar,Prodigy)测量了脊柱骨密度(BMD)。在测量BMD时评估了身高、体重、体重指数和 Tanner分期。共有16.1%的患者骨量正常(Z≥-1),22.6%的患者骨量减少(Z=-1至-2),61.3%的患者骨量低(Z≤-2)。BMD Z与身高和体重Z评分相关。约53.9%的受试者性腺功能正常,46.1%的受试者使用性腺类固醇诱导青春期。BMD Z随年龄显著恶化(P<.0001)。然而,性腺功能正常与诱导青春期的受试者之间LBM患病率没有差异:性腺功能正常的受试者中71.4%的BMD Z为-2或更低,而诱导青春期的受试者中这一比例为66.7%。我们的结果表明,无论输血和螯合方案是否充分,Thal青少年中LBM的患病率都很高。发现正常或诱导青春期的青少年骨量增加不理想。因此,对于青少年Thal患者,应评估补充钙和维生素D以及抗吸收治疗,并密切监测生长和性发育。